

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[Back](#)

[In the News](#)

[About Our Center & Treatment](#)

[Refer a Patient](#)

[Research](#)

[Clinical Trials](#)

[Patient Resources](#)

[Support & Advocacy](#)

[Education & Career](#)

[Contact Us](#)

[Locations](#)

[About Us](#)

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Equality, diversity & inclusion](#)

[Annual report](#)

[Give to MSK](#)

[Center](#)

[He comes to Memorial Sloan Kettering from Cold Spring Harbor Laboratory, where he was](#)

[Deputy Director of the Cancer Center.](#)

[Dr. Lowe studies the genes and processes whose alterations cause and maintain cancer. Historically](#)

[much of his work has focused on the tumor suppressor gene *p53*, which is mutated in about half of all](#)

[cancers. His work has shown how changes in *p53* can lead to the development of tumors and how the](#)

[disruption of *p53* can affect a tumor's response to therapy, leading to drug resistance. More recently, Dr. Lowe has developed strategies for identifying](#)

[many new tumor suppressor genes, as well as genes whose continued activity is required for cancer progression and whose inhibition leads to cancer](#)

[regression.](#)

[His research also has centered on the development of mouse models for understanding how cancer progresses and responds to therapy. Some of these](#)

[models allow researchers to make sense of apoptosis \(programmed cell death\) and senescence \(biological aging\) so that these processes can be](#)

[restored to cancer cells, thereby allowing traditional chemotherapy drugs to destroy them. In addition, Dr. Lowe has used a technique called RNA](#)

[interference to more closely regulate the expression of genes in mice, making genetic alterations more precise and specific. This method also enables](#)

[Dr. Lowe to search for therapeutic targets for new cancer drugs or drug combinations.](#)

["Scott is a world leader in efforts to understand the cellular mechanisms that suppress tumor formation and control responses to chemotherapeutic](#)

[drugs," according to \[Thomas J. Kelly\]\(#\), Director of Sloan Kettering Institute. "He is a wonderful addition to SKI."](#)

[Dr. Lowe, a Howard Hughes Medical Institute investigator, received his PhD degree in biology from the Massachusetts Institute of Technology. In 2005,](#)

[he won the Center's Paul A. Marks Prize for Cancer Research. He has also received awards from the American Association for Cancer Research and](#)

[the Association for International Cancer Research. He is the incumbent of the Geoffrey Beene Chair in Cancer Biology.](#)

[- Connect](#)

[Contact us](#)

[Locations](#)

[About Us](#)

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Equality, diversity & inclusion](#)

[Annual report](#)

[Give to MSK](#)

[Center](#)

[He comes to Memorial Sloan Kettering from Cold Spring Harbor Laboratory, where he was](#)

[Deputy Director of the Cancer Center.](#)

[Dr. Lowe studies the genes and processes whose alterations cause and maintain cancer. Historically](#)

[much of his work has focused on the tumor suppressor gene *p53*, which is mutated in about half of all](#)

[cancers. His work has shown how changes in *p53* can lead to the development of tumors and how the](#)

[disruption of *p53* can affect a tumor's response to therapy, leading to drug resistance. More recently, Dr. Lowe has developed strategies for identifying](#)

[many new tumor suppressor genes, as well as genes whose continued activity is required for cancer progression and whose inhibition leads to cancer](#)

[regression.](#)

[His research also has centered on the development of mouse models for understanding how cancer progresses and responds to therapy. Some of these](#)

[models allow researchers to make sense of apoptosis \(programmed cell death\) and senescence \(biological aging\) so that these processes can be](#)

[restored to cancer cells, thereby allowing traditional chemotherapy drugs to destroy them. In addition, Dr. Lowe has used a technique called RNA](#)

[interference to more closely regulate the expression of genes in mice, making genetic alterations more precise and specific. This method also enables](#)

[Dr. Lowe to search for therapeutic targets for new cancer drugs or drug combinations.](#)

["Scott is a world leader in efforts to understand the cellular mechanisms that suppress tumor formation and control responses to chemotherapeutic](#)

[drugs," according to \[Thomas J. Kelly\]\(#\), Director of Sloan Kettering Institute. "He is a wonderful addition to SKI."](#)

[Dr. Lowe, a Howard Hughes Medical Institute investigator, received his PhD degree in biology from the Massachusetts Institute of Technology. In 2005,](#)

[he won the Center's Paul A. Marks Prize for Cancer Research. He has also received awards from the American Association for Cancer Research and](#)

[the Association for International Cancer Research. He is the incumbent of the Geoffrey Beene Chair in Cancer Biology.](#)



Scott W. Lowe

APPOINTMENTS

[800-525-2225](#)



▾ About MSK

[About us](#)

[Careers](#) ■

[Giving](#) ■

▾ Cancer Care

[Adult cancer types](#)

[Child & teen cancer types](#)

[Integrative medicine](#)

[Nutrition & cancer](#)

[Find a doctor](#)

▾ Research & Education

[Sloan Kettering Institute](#)

[Gerstner Sloan Kettering Graduate School](#) ■

[Graduate medical education](#)

[MSK Library](#) ■

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility statement](#)

[Privacy policy](#)

[Price transparency](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center